Cellectar Biosciences CLRB 深 沪
等待开盘 06-25 09:30:00 美东时间
2.5644
+0.064
+2.58%
华盛通- 最 高2.565
- 今 开2.50
- 成交量 1.06万股
- 最 低 2.50
- 昨 收 2.50
- 总市值 2049.42万
- 52周最高 6.52
- 市盈率 静 --
- 换手率 0.13%
- 52周最低 2.20
- 委 比 -36.51%
- 总股本 799.18万
- 历史最高 276000.00
- 量 比 0.09
- 振 幅 2.60%
- 历史最低 2.20
- 每 手 1
- 风险率 1.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cellectar Biosciences To Highlight Efficacy Results From Phase 2 CLOVER WaM Clinical Trial Of Iopofosine I 131 To Treat r/r WM At 2026 ASCO
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi TherapyPlans to Initiate Phase 3 Confirmatory
06-01 20:15
Cellectar Biosciences Bets on Iopofosine Breakthrough
Cellectar Biosciences Inc (($CLRB)) has held its Q1 earnings call. Read on for ...
05-20 13:19
Cellectar Biosciences Announces Board Changes and New Director
The latest announcement is out from Cellectar Biosciences ( ($CLRB) ). On May 1...
05-19 06:01
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
Ladenburg Thalmann Assumes Cellectar Biosciences at Buy, Announces Price Target of $10
Ladenburg Thalmann analyst Kevin DeGeeter assumes Cellectar Biosciences (NASDAQ:CLRB) with a Buy rating and announces Price Target of $10.
05-16 03:31
Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call
Cellectar Biosciences (NASDAQ:CLRB) reported first-quarter financial results on...
05-14 20:59
Cellectar Biosciences Q1 net loss narrows, completes $140 mln financing
Cellectar Biosciences Q1 net loss narrows, completes $140 mln financing Overview US biopharma firm's Q1 net loss narrowed from prior year Company completed financing of up to $140 mln to support lead drug and regulatory plans Positive 12-month follow-up data for iopofosine I 131 in Waldenström Macro
05-14 19:23
Cellectar Biosciences Non-GAAP EPS of -$1.33
Cellectar Biosciences press release (CLRB): Q1 Non-GAAP EPS of -$1.33. As of March 31, 2026, the company had cash and cash equivalents of $8.3 million, compared to $13.2 million as of December 31, 202...
05-14 19:18
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Cellectar Biosciences Q1 EPS $(1.33) Beats $(1.89) Estimate. Cash And Equivalents $8.35M
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(1.33) per share which beat the analyst consensus estimate of $(1.89) by 29.26 percent. This is a 69.07 percent increase over losses of $(4.30) per share
05-14 19:08
